vs
AVANOS MEDICAL, INC.（AVNS）与Rapid7, Inc.（RPD）财务数据对比。点击上方公司名可切换其他公司
Rapid7, Inc.的季度营收约是AVANOS MEDICAL, INC.的1.2倍（$217.4M vs $180.9M），Rapid7, Inc.净利率更高（1.4% vs -0.7%，领先2.2%），AVANOS MEDICAL, INC.同比增速更快（0.7% vs 0.5%），Rapid7, Inc.自由现金流更多（$36.4M vs $21.3M），过去两年AVANOS MEDICAL, INC.的营收复合增速更高（4.4% vs 3.0%）
Avanos Medical是一家医疗科技企业，专注于研发生产临床医疗设备，核心业务围绕疼痛管理与慢性护理两大板块展开，致力于帮助患者加快康复、预防感染，同时减少临床治疗中阿片类药物的使用。
Rapid7是全球领先的网络安全企业，提供漏洞管理、威胁检测与响应、云安全、安全分析等全系列安全解决方案，服务全球科技、医疗、金融、制造等行业的各类规模企业及公共部门客户，助力客户高效识别、应对和缓解网络安全风险。
AVNS vs RPD — 直观对比
营收规模更大
RPD
是对方的1.2倍
$180.9M
营收增速更快
AVNS
高出0.2%
0.5%
净利率更高
RPD
高出2.2%
-0.7%
自由现金流更多
RPD
多$15.1M
$21.3M
两年增速更快
AVNS
近两年复合增速
3.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $180.9M | $217.4M |
| 净利润 | $-1.3M | $3.1M |
| 毛利率 | 47.5% | 68.9% |
| 营业利润率 | 1.4% | 1.0% |
| 净利率 | -0.7% | 1.4% |
| 营收同比 | 0.7% | 0.5% |
| 净利润同比 | 99.7% | 44.1% |
| 每股收益（稀释后） | $-0.02 | $0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AVNSRPD
| Q4 25 | $180.9M | $217.4M | ||
| Q3 25 | $177.8M | $218.0M | ||
| Q2 25 | $175.0M | $214.2M | ||
| Q1 25 | $167.5M | $210.3M | ||
| Q4 24 | $179.6M | $216.3M | ||
| Q3 24 | $170.4M | $214.7M | ||
| Q2 24 | $171.7M | $208.0M | ||
| Q1 24 | $166.1M | $205.1M |
净利润AVNSRPD
| Q4 25 | $-1.3M | $3.1M | ||
| Q3 25 | $-1.4M | $9.8M | ||
| Q2 25 | $-76.8M | $8.3M | ||
| Q1 25 | $6.6M | $2.1M | ||
| Q4 24 | $-397.3M | $2.2M | ||
| Q3 24 | $4.3M | $15.4M | ||
| Q2 24 | $1.8M | $6.5M | ||
| Q1 24 | $-900.0K | $1.4M |
毛利率AVNSRPD
| Q4 25 | 47.5% | 68.9% | ||
| Q3 25 | 48.4% | 70.2% | ||
| Q2 25 | 52.6% | 70.6% | ||
| Q1 25 | 53.6% | 71.7% | ||
| Q4 24 | 54.6% | 69.5% | ||
| Q3 24 | 54.5% | 70.6% | ||
| Q2 24 | 55.7% | 70.7% | ||
| Q1 24 | 57.1% | 70.3% |
营业利润率AVNSRPD
| Q4 25 | 1.4% | 1.0% | ||
| Q3 25 | 0.1% | 2.7% | ||
| Q2 25 | -42.6% | 1.6% | ||
| Q1 25 | 6.1% | -0.0% | ||
| Q4 24 | -233.0% | 3.4% | ||
| Q3 24 | 7.0% | 6.0% | ||
| Q2 24 | 3.7% | 2.5% | ||
| Q1 24 | 2.4% | 4.7% |
净利率AVNSRPD
| Q4 25 | -0.7% | 1.4% | ||
| Q3 25 | -0.8% | 4.5% | ||
| Q2 25 | -43.9% | 3.9% | ||
| Q1 25 | 3.9% | 1.0% | ||
| Q4 24 | -221.2% | 1.0% | ||
| Q3 24 | 2.5% | 7.2% | ||
| Q2 24 | 1.0% | 3.1% | ||
| Q1 24 | -0.5% | 0.7% |
每股收益（稀释后）AVNSRPD
| Q4 25 | $-0.02 | $0.05 | ||
| Q3 25 | $-0.03 | $0.15 | ||
| Q2 25 | $-1.66 | $0.13 | ||
| Q1 25 | $0.14 | $0.03 | ||
| Q4 24 | $-8.64 | $0.08 | ||
| Q3 24 | $0.09 | $0.21 | ||
| Q2 24 | $0.04 | $0.09 | ||
| Q1 24 | $-0.02 | $0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $89.8M | $474.7M |
| 总债务越低越好 | $90.3M | — |
| 股东权益账面价值 | $778.2M | $154.7M |
| 总资产 | $1.1B | $1.7B |
| 负债/权益比越低杠杆越低 | 0.12× | — |
8季度趋势，按日历期对齐
现金及短期投资AVNSRPD
| Q4 25 | $89.8M | $474.7M | ||
| Q3 25 | $70.5M | $407.1M | ||
| Q2 25 | $90.3M | $511.7M | ||
| Q1 25 | $97.0M | $493.5M | ||
| Q4 24 | $107.7M | $521.7M | ||
| Q3 24 | $89.0M | $443.7M | ||
| Q2 24 | $92.2M | $442.6M | ||
| Q1 24 | $75.8M | $411.7M |
总债务AVNSRPD
| Q4 25 | $90.3M | — | ||
| Q3 25 | $93.4M | — | ||
| Q2 25 | $95.7M | — | ||
| Q1 25 | $98.0M | — | ||
| Q4 24 | $125.3M | — | ||
| Q3 24 | $152.6M | — | ||
| Q2 24 | $164.9M | — | ||
| Q1 24 | $167.2M | — |
股东权益AVNSRPD
| Q4 25 | $778.2M | $154.7M | ||
| Q3 25 | $778.0M | $127.2M | ||
| Q2 25 | $776.3M | $90.4M | ||
| Q1 25 | $839.4M | $52.7M | ||
| Q4 24 | $828.5M | $17.7M | ||
| Q3 24 | $1.2B | $-5.1M | ||
| Q2 24 | $1.2B | $-52.6M | ||
| Q1 24 | $1.2B | $-86.4M |
总资产AVNSRPD
| Q4 25 | $1.1B | $1.7B | ||
| Q3 25 | $1.1B | $1.7B | ||
| Q2 25 | $1.0B | $1.6B | ||
| Q1 25 | $1.1B | $1.6B | ||
| Q4 24 | $1.2B | $1.7B | ||
| Q3 24 | $1.7B | $1.6B | ||
| Q2 24 | $1.7B | $1.5B | ||
| Q1 24 | $1.7B | $1.5B |
负债/权益比AVNSRPD
| Q4 25 | 0.12× | — | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.12× | — | ||
| Q1 25 | 0.12× | — | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.12× | — | ||
| Q2 24 | 0.13× | — | ||
| Q1 24 | 0.14× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $28.2M | $37.6M |
| 自由现金流经营现金流 - 资本支出 | $21.3M | $36.4M |
| 自由现金流率自由现金流/营收 | 11.8% | 16.8% |
| 资本支出强度资本支出/营收 | 3.8% | 0.5% |
| 现金转化率经营现金流/净利润 | — | 12.01× |
| 过去12个月自由现金流最近4个季度 | $43.1M | $146.2M |
8季度趋势，按日历期对齐
经营现金流AVNSRPD
| Q4 25 | $28.2M | $37.6M | ||
| Q3 25 | $14.0M | $39.0M | ||
| Q2 25 | $6.8M | $47.5M | ||
| Q1 25 | $25.7M | $29.8M | ||
| Q4 24 | $57.9M | $63.8M | ||
| Q3 24 | $23.0M | $44.0M | ||
| Q2 24 | $27.8M | $32.9M | ||
| Q1 24 | $-8.0M | $31.1M |
自由现金流AVNSRPD
| Q4 25 | $21.3M | $36.4M | ||
| Q3 25 | $7.0M | $34.8M | ||
| Q2 25 | $-4.2M | $46.6M | ||
| Q1 25 | $19.0M | $28.4M | ||
| Q4 24 | $53.1M | $62.6M | ||
| Q3 24 | $20.0M | $42.6M | ||
| Q2 24 | $21.9M | $32.6M | ||
| Q1 24 | $-12.1M | $30.4M |
自由现金流率AVNSRPD
| Q4 25 | 11.8% | 16.8% | ||
| Q3 25 | 3.9% | 16.0% | ||
| Q2 25 | -2.4% | 21.8% | ||
| Q1 25 | 11.3% | 13.5% | ||
| Q4 24 | 29.6% | 28.9% | ||
| Q3 24 | 11.7% | 19.9% | ||
| Q2 24 | 12.8% | 15.7% | ||
| Q1 24 | -7.3% | 14.8% |
资本支出强度AVNSRPD
| Q4 25 | 3.8% | 0.5% | ||
| Q3 25 | 3.9% | 1.9% | ||
| Q2 25 | 6.3% | 0.4% | ||
| Q1 25 | 4.0% | 0.6% | ||
| Q4 24 | 2.7% | 0.5% | ||
| Q3 24 | 1.8% | 0.6% | ||
| Q2 24 | 3.4% | 0.1% | ||
| Q1 24 | 2.5% | 0.3% |
现金转化率AVNSRPD
| Q4 25 | — | 12.01× | ||
| Q3 25 | — | 3.97× | ||
| Q2 25 | — | 5.70× | ||
| Q1 25 | 3.89× | 14.14× | ||
| Q4 24 | — | 29.36× | ||
| Q3 24 | 5.35× | 2.85× | ||
| Q2 24 | 15.44× | 5.03× | ||
| Q1 24 | — | 22.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
RPD
| Products | $209.1M | 96% |
| Services | $8.2M | 4% |
